Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified February 2014 by Columbia University
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University
ClinicalTrials.gov Identifier:
NCT02066532
First received: February 18, 2014
Last updated: NA
Last verified: February 2014
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)